Liminatus Pharma LLCLIMN
13F holders, Q3 2025 (September 30)10holders
3new positions
3sold out
$1.67avg. 13F price*
At the end of Q3 2025, 10 institutions reported holding Liminatus Pharma LLC (LIMN) in their 13F filings, unchanged from Q2 2025. 3 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($123K), Geode Capital Management, LLC ($106K) and UBS Group AG ($68K).
- Company
- Liminatus Pharma LLC
- CUSIP
- 53271X108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $84K |
| Exits | 3 | $35K |
All 13F filers, Q2 2025 → Q3 2025: 60,451 shares bought and 3,229 shares sold, net +57,222 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Vanguard Group Inc. | 0.00% | No change | 73,424 | $123K |
| Geode Capital Management, LLC | 0.00% | Reduce -0.2% | 63,734 | $106K |
| UBS Group AG | 0.00% | Add +28.7% | 40,526 | $68K |
| Jane Street Group, LLC | 0.00% | New | 39,635 | $66K |
| State Street Corp. | 0.00% | No change | 19,000 | $32K |
| BlackRock, Inc. | 0.00% | No change | 13,255 | $22K |
| Squarepoint Ops LLC | 0.00% | New | 10,403 | $17K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +263.8% | 1,848 | $3K |
| Bank of America Corp. | 0.00% | Add +3.0% | 68 | $113 |
| Farther Finance Advisors, LLC | 0.00% | New | 31 | $52 |
"% of holder's portfolio" is LIMN's weight in each manager's 13F, not the share of Liminatus Pharma LLC the manager owns.